Change in hepatocyte growth factor concentration promote mesenchymal stem cell-mediated osteogenic regeneration

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 6, 2012, Pages 1260-1273

  Wen, Qian ^a   Zhou, Liang ^b   Zhou, Chaoying ^a   Zhou, Mingqian ^a   Luo, Wei ^a   Ma, Li ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

Avascular necrosis of femoral head; Hepatocyte growth factor; Mesenchymal stem cells; Osteogenic differentiation; Proliferation

Indexed keywords

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 84861566211     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01407.x     Document Type: Article

References (50)

1. Satija N, Gurudutta G, Sharma S, et al. Mesenchymal stem cells: molecular targets for tissue engineering. Stem Cells Dev. 2007; 16: 7-23.
2. Gangji V, Hauzeur J, Matos C, et al. Treatment of osteonecrosis of the femoral head with implantation of autologous bone-marrow cells. A pilot study. J Bone Joint Surg Am. 2004; 86: 1153-60.
3. Daltro G, Fortuna V, Araújo M, et al. Femoral head necrosis treatment with autologous stem cells in sickle cell disease. Acta Ortop Bras. 2008; 16: 23-7.
4. Stamm C, Westphal B, Kleine H, et al. Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet. 2003; 361: 45-6.
5. Sch chinger V, Erbs S, Elssser A, et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med. 2006; 355: 1210-21.
6. Kinnaird T, Stabile E, Burnett M, et al. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res. 2004; 94: 678-85.
7. Noji S, Tashiro K, Koyama E, et al. Expression of hepatocyte growth factor gene in endothelial and Kupffer cells of damaged rat livers, as revealed by in situ hybridization. Biochem Biophys Res Commun. 1990; 173: 42-7.
8. Fujimoto J. Gene therapy for liver cirrhosis. J Gastroenterol Hepatol. 2000; 15: D33-6.
9. Yasuda S, Goto Y, Baba T, et al. Enhanced secretion of cardiac hepatocyte growth factor from an infarct region is associated with less severe ventricular enlargement and improved cardiac function. J Am Coll Cardiol. 2000; 36: 115-21.
10. Xin X, Yang S, Ingle G, et al. Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Am J Pathol. 2001; 158: 1111-20.
11. Sheehan S, Tatsumi R, Temm-Grove C, et al. HGF is an autocrine growth factor for skeletal muscle satellite cells in vitro. Muscle Nerve. 2000; 23: 239-45.
12. Forte G, Minieri M, Cossa P, et al. Hepatocyte growth factor effects on mesenchymal stem cells: proliferation, migration, and differentiation. Stem Cells. 2006; 24: 23-33.
13. Neuss S, Becher E, Wltje M, et al. Functional expression of HGF and HGF receptor/c-met in adult human mesenchymal stem cells suggests a role in cell mobilization, tissue repair, and wound healing. Stem Cells. 2004; 22: 405-14.
14. Duan H, Wu C, Wu D, et al. Treatment of myocardial ischemia with bone marrow-derived mesenchymal stem cells overexpressing hepatocyte growth factor. Molecular Therapy. 2003; 8: 467-74.
15. Cai L, Johnstone B, Cook T, et al. Suppression of hepatocyte growth factor production impairs the ability of adipose-derived stem cells to promote ischemic tissue revascularization. Stem Cells. 2007; 25: 3234-43.
16. Wen Q, Ma L, Chen Y, et al. Treatment of avascular necrosis of the femoral head by hepatocyte growth factor-transgenic bone marrow stromal stem cells. Gene Therapy. 2008; 15: 1523-35.
17. Standal T, Abildgaard N, Fagerli U, et al. HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood. 2007; 109: 3024-30.
18. Leshem Y, Spicer D, Gal-Levi R, et al. Hepatocyte growth factor (HGF) inhibits skeletal muscle cell differentiation: a role for the bHLH protein twist and the cdk inhibitor p27. J Cell Physiol. 2000; 184: 101-9.
19. D'Ippolito G, Schiller P, Perez-stable C, et al. Cooperative actions of hepatocyte growth factor and 1, 25-dihydroxyvitamin D3 in osteoblastic differentiation of human vertebral bone marrow stromal cells. Bone. 2002; 31: 269-75.
20. Salic A, Mitchison TJ. A chemical method for fast and sensitive detection of DNA synthesis in vivo. Proc Natl Acad Sci U S A. 2008; 105: 2415-20.
21. Momcilovi O, Choi S, Varum S, et al. Ionizing radiation induces ataxia telangiectasia mutated-dependent checkpoint signaling and G (2) but not G (1) cell cycle arrest in pluripotent human embryonic stem cells. Stem Cells. 2009; 27: 1822-35.
22. Takasu H, Sugita A, Uchiyama Y, et al. c-Fos protein as a target of anti-osteoclastogenic action of vitamin D, and synthesis of new analogs. Clin Res. 2006; 116: 528-35.
23. Ali-Benali M, Alary R, Joudrier P, et al. Comparative expression of five Lea Genes during wheat seed development and in response to abiotic stresses by real-time quantitative RT-PCR. Biochim. Biophys Acta. 2005; 1730: 56-65.
24. Wen Q, Ma L, Chen Y, et al. A rabbit model of hormone-induced early avascular necrosis of the femoral head. Biomed Environ Sci. 2008; 21: 398-403.
25. Rosová I, Link D, Nolta J. shRNA-mediated decreases in c-Met levels affect the differentiation potential of human mesenchymal stem cells and reduce their capacity for tissue repair. Tissue Eng Part A. 2010; 16: 2627-39.
26. Comoglio P. Pathway specificity for Met signalling. Nat Cell Biol. 2001; 3: E161-2.
27. Crews C, Alessandrini A, Erikson R. The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. Science. 1992; 258: 478-80.
28. Leevers S, Paterson H, Marshall C. Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature. 1994; 369: 411-4.
29. Rosen L, Ginty D, Weber M, et al. Membrane depolarization and calcium influx stimulate MEK and MAP kinase via activation of Ras. Neuron. 1994; 12: 1207-21.
30. Cowley S, Paterson H, Kemp P, et al. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell. 1994; 77: 841-52.
31. Nakanishi S, Kakita S, Takahashi I, et al. Wortmannin, a microbial product inhibitor of myosin light chain kinase. J Biol Chem. 1992; 267: 2157-63.
32. Arcaro A, Wymann MP. Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3, 4, 5-trisphosphate in neutrophil responses. Biochem J. 1993; 296: 297-301.
33. Komori T, Yagi H, Nomura S, et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell. 1997; 89: 755-64.
34. Otto F, Thornell A, Crompton T, et al. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell. 1997; 89: 765-71.
35. Ducy P, Zhang R, Geoffroy V, et al. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell. 1997; 89: 747-54.
36. Nakashima K, Zhou X, Kunkel G, et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell. 2002; 108: 17-29.
37. Rosová I, Dao M, Capoccia B, et al. Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells. Stem Cells. 2008; 26: 2173-82.
38. Sato T, Fujieda H, Murao S, et al. Sequential changes of hepatocyte growth factor in the serum and enhanced c-Met expression in the myocardium in acute myocardial infarction. Jpn Circ J. 1999; 63: 906-8.
39. Nakamura T, Nawa K, Ichihara A. Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun. 1984; 122: 1450-9.
40. Nakamura T, Nishizawa T, Hagiya M, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature. 1989; 342: 440-3.
41. Sonnenberg E, Meyer D, Weidner K, et al. Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development. J Cell Biol. 1993; 123: 223-35.
42. Paku S, Schnur J, Nagy P, et al. Origin and structural evolution of the early proliferating oval cells in rat liver. Am J Pathol. 2001; 158: 1313-23.
43. Nabel EG. Gene therapy for cardiovascular disease. Circulation. 1995; 91: 541-8.
44. Hayashi S, Morishita R, Nakamura S, et al. Potential role of hepatocyte growth factor, a novel angiogenic growth factor, in peripheral arterial disease: downregulation of HGF in response to hypoxia in vascular cells. Circulation. 1999; 100: II301-8.
45. Morishita R, Makino H, Aoki M, et al. Phase I/iia clinical trial of therapeutic angiogenesis using hepatocyte growth factor gene transfer to treat critical limb ischemia. Arterioscler Thromb Vasc Biol. 2011; 31: 713-20.
46. Rastogi S, Guerrero M, Wang M, et al. Myocardial transfection with naked DNA plasmid encoding hepatocyte growth factor prevents the progression of heart failure in dogs. Am J Physiol Heart Circ Physiol. 2011; 300: H1501-9.
47. Weinstein R, Jilka R, Parfitt A, et al. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest. 1998; 102: 274-82.
48. Gentile A, Trusolino L, Comoglio P. The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev. 2008; 27: 85-94.
49. Yanagita K, Matsumoto K, Sekiguchi K, et al. Hepatocyte growth factor may act as a pulmotrophic factor on lung regeneration after acute lung injury. J Biol Chem. 1993; 268: 21212-7.
50. Birchmeier C, Birchmeier W, Gherardi E, et al. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003; 4: 915-25.